BLISSGVS / NSE / Biotechnology & Drugs
Bliss GVS Pharma
1Y Price Trend
Key Information
Recommendations
Target High462.7
Target Low118.35
Target Mean0
Target Median0
Risk Metrics
Overall RiskHigh risk
Board Risk63.34
Key Analysis
Overall score, performance score, return rating, defensive, aggressive, and balanced views.
Download appProjection Analytics
Best-case, base-case, worst-case, and dynamic AI projection views.
Download appLatest stock news
SN Kamath appointed MD, Bliss GVS Pharma Ltd Whispers In The Corridors
Anupam Rasayan launches open offer for Bliss GVS Pharma after acquiring 43.3% stake CNBC TV18
Anupam Rasayan files draft offer for Bliss GVS scanx.trade
Anupam Rasayan targets 25-30% revenue recovery in FY27 following strategic Bliss GVS Pharma acquisition MSN
Anupam Rasayan to acquire up to 43% stake in Bliss GVS Pharma for around Rs 1,369 crore MSN
Bliss GVS Pharma Ltd hits 52-week high of ₹447 Amid WHO Approval, Strong Earnings and Acquisition Boost India Infoline
Bliss GVS Pharma rises on securing Inspection Closure Report from WHO Investment Guru India
Stocks to Watch Today: Infosys, Bliss GVS Pharma, Vedanta, John Cockerill, Concord Biotech, Rajnandini... Moneycontrol.com
© SharekeyX | Rusaka Technologies 2024-2026